RACTIGEN THERAPEUTICS ANNOUNCES U.S. FDA IND CLEARANCE FOR FIRST-IN-CLASS SARNA CANDIDATE RAG-1C TO TREAT PROLIFERATIVE VITREORETINOPATHY

Reuters · 1d ago

Please log in to view news